Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405

Status	RECRUITING
Phase	Phase 2
Sponsor	Blueprint Medicines Corporation
Enrollment	105 participants

Key Eligibility Criteria

Inclusion (2)

- Part A: Confirmed diagnosis of CIndU for e3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines.
- Part B: Confirmed diagnosis of CSU for e3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines.

Exclusion (6)

- Part A: Any active urticaria that may interfere with study assessments.
- Part B: Participant has a clearly defined predominant cause of chronic urticaria or sole trigger such as symptomatic dermographism and cold-induced urticaria.
- Part A and Part B: Any other skin disease associated with chronic itching or angioedema that might influence the study evaluations and results, skin diseases associated with only wheals and no itch, or autoinflammatory diseases with urticarial lesions.
- Part A and Part B: Significant medical, psychiatric, or surgical conditions, or physical findings that may affect participant safety, study drug metabolism, study participation, or assessment of study results.
- Part A and Part B: Abnormal laboratory values that may pose risks or interfere with study participation.

... and 1 more (see full listing online)

Locations (47 total)

Allervie Clinical Research, Birmingham, Alabama, United States
Acuro Research, Inc., Little Rock, Arkansas, United States
Modena Allergy & Asthma Clinical Research - La Jolla, La Jolla, California, United States
... and 44 more locations